SEC. 3. INTERAGENCY PULMONARY HYPERTENSION CO-
ORDINATING COMMITTEE. 
(a) ESTABLISHMENT.—The Secretary of Health and 
Human Services (in this Act referred to as the ‘‘Sec-
retary’’) shall establish a committee, to be known as the 
‘‘Interagency Pulmonary Hypertension Coordinating Com-
mittee’’ (in this Act referred to as the ‘‘Committee’’), to 
make recommendations on, and coordinate, all efforts 
within the Department of Health and Human Services 
concerning pulmonary hypertension. 
(b) RESPONSIBILITIES.—In carrying out its duties 
under this section, the Committee shall— 
(1) develop and annually update a summary of 
pulmonary hypertension advances in medical re-
search and treatment development and improvement, 
early and accurate diagnosis, appropriate and timely 
intervention, transplantation, and access to care and 
therapies for patients; 
(2) monitor Federal activities with respect to 
pulmonary hypertension; 
(3) make recommendations to the Secretary re-
garding appropriate changes to such activities, in-
cluding recommendations with respect to the stra-
tegic plan developed under paragraph (5); 
VerDate Mar 15 2010 
20:11 May 24, 2013
Jkt 029200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H2073.IH
H2073
tkelley on DSK3SPTVN1PROD with BILLS
(4) make recommendations to the Secretary re-
garding stakeholder participation in decisions relat-
ing to pulmonary hypertension; 
(5) develop and annually update a comprehen-
sive strategic plan to cooperatively improve health 
outcomes for pulmonary hypertension patients which 
includes— 
(A) recommendations to improve profes-
sional education concerning accurate diagnosis 
and appropriate intervention for health care 
providers; 
(B) recommendations to improve the trans-
plantation criteria and process concerning lung 
and heart-lung transplants for pulmonary hy-
pertension patients; 
(C) recommendations to improve public 
awareness and recognition of pulmonary hyper-
tension; 
(D) recommendations to improve health 
care delivery and promote early and accurate 
diagnosis for pulmonary hypertension patients; 
and 
(E) recommendations to systematically ad-
vance the full spectrum of biomedical research, 
including specific recommendations for basic, 
VerDate Mar 15 2010 
20:11 May 24, 2013
Jkt 029200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2073.IH
H2073
tkelley on DSK3SPTVN1PROD with BILLS
translational, clinical, and pediatric research, 
and research training and career development; 
and 
(6) submit to the Congress the strategic plan 
under paragraph (5) and any updates to such plan. 
(c) MEMBERSHIP.— 
(1) IN
GENERAL.—The Committee shall be 
composed of— 
(A) the Administrator of the Health Re-
sources and Services Administration; 
(B) the Director of the Centers for Disease 
Control and Prevention and the directors of 
such centers at the Centers for Disease Control 
and Prevention as the Secretary determines ap-
propriate; 
(C) the Director of the National Institutes 
of Health and the directors of such institutes, 
centers, and offices at the National Institutes of 
Health as the Secretary determines appropriate; 
(D) the Director of the Agency for 
Healthcare Research and Quality; 
(E) the Commissioner of Food and Drugs 
and the directors of such centers and offices at 
the Food and Drug Administration as the Sec-
retary determines appropriate; 
VerDate Mar 15 2010 
20:11 May 24, 2013
Jkt 029200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2073.IH
H2073
tkelley on DSK3SPTVN1PROD with BILLS
(F) the heads of other relevant agencies as 
the Secretary deems appropriate; and 
(G) the additional members appointed 
under paragraph (2). 
(2) ADDITIONAL MEMBERS.—Not fewer than 6 
members of the Committee or 1⁄3 of the total mem-
bership of the Committee, whichever is greater, shall 
be composed of non-Federal public members to be 
appointed by the Secretary, of which— 
(A) at least one such member shall be an 
individual with a diagnosis of pulmonary hyper-
tension; 
(B) at least one such member shall be the 
primary caregiver for an individual with a diag-
nosis of pulmonary hypertension; and 
(C) at least one such member shall be a 
representative of a leading research, advocacy, 
and support organization primarily serving indi-
viduals with a diagnosis of pulmonary hyper-
tension. 
(d) ADMINISTRATIVE SUPPORT; TERMS OF SERVICE; 
OTHER PROVISIONS.—The following provisions shall apply 
with respect to the Committee: 
VerDate Mar 15 2010 
23:02 May 24, 2013
Jkt 029200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2073.IH
H2073
tkelley on DSK3SPTVN1PROD with BILLS
(1) The Committee shall receive necessary and 
appropriate administrative support from the Sec-
retary. 
(2) Members of the Committee appointed under 
subsection (c)(2) shall serve for a term of 4 years, 
and may be appointed for one or more additional 4- 
year terms. Any member appointed to fill a vacancy 
for an unexpired term shall be appointed for the re-
mainder of such term. A member may serve after 
the expiration of the member’s term until a suc-
cessor has taken office. 
(3) The Committee shall meet at the call of the 
chairperson or upon the request of the Secretary. 
The Committee shall meet not fewer than two times 
each year. 
(4) All meetings of the Committee shall be pub-
lic and shall include appropriate time periods for 
questions and presentations by the public. 
(e) SUBCOMMITTEES; ESTABLISHMENT AND MEM-
BERSHIP.—In carrying out its functions, the Committee 
may establish subcommittees and convene workshops and 
conferences. Such subcommittees shall be composed of 
Committee members and may hold such meetings as are 
necessary to enable the subcommittees to carry out their 
duties. 
VerDate Mar 15 2010 
20:11 May 24, 2013
Jkt 029200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2073.IH
H2073
tkelley on DSK3SPTVN1PROD with BILLS
(f) SUNSET.—This section shall not apply after Sep-
tember 30, 2019, and the Committee shall be terminated 
on such date. 
SEC. 4. REPORT TO CONGRESS. 
(a) IN GENERAL.—On a biennial basis after the date 
of enactment of this Act, the Secretary, in coordination 
with the Committee, shall prepare and submit to the Com-
mittee on Health, Education, Labor, and Pensions of the 
Senate and the Committee on Energy and Commerce 
Committee of the House of Representatives a progress re-
port on activities related to improving health outcomes for 
pulmonary hypertension patients. 
(b) CONTENTS.—The report submitted under sub-
section (a) shall contain— 
(1) information on the incidence of pulmonary 
hypertension and trend data of such incidence since 
the date of enactment of the Pulmonary Hyper-
tension Research and Diagnosis Act of 2013; 
(2) information on the average time between 
initial screening and accurate diagnosis as well as 
the average stage of pulmonary hypertension when 
appropriate intervention begins and up-to-date, re-
lated trend data; 
VerDate Mar 15 2010 
20:11 May 24, 2013
Jkt 029200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H2073.IH
H2073
tkelley on DSK3SPTVN1PROD with BILLS